leflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 88 Diseases   68 Trials   68 Trials   2888 News 


«12...2122232425262728293031...3536»
  • ||||||||||  leflunomide / Generic mfg.
    [VIRTUAL] Leflunomide Induced Eosinophilic Bronchitis (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_5286;    
    After discontinuing the leflunomide, first line treatment is corticosteroids. Eosinophilic bronchitis should be considered in the differential diagnosis of cough for all patients to whom leflunomide is prescribed.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    [VIRTUAL] Optic Neuritis in Sarcoidosis: Clinical Features and Response to Therapy (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_2891;    
    Current or past treatment for optic neuritis included prednisone in 39 (97.5%), methotrexate in 35 (87.5%), azathioprine in 16 (40%), leflunomide in 8 (20%) and mycophenolate in 3 (7.5%)...All 15 patients received infliximab, with five switched to adalimumab because of reactions to infliximab...It usually requires second and third line therapy. Anti-TNF therapy led to stabilization or improvement of eye disease with reduction of glucocorticoid use in most patients.
  • ||||||||||  Vistide (cidofovir) / Gilead, cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4573;    
    Patients who do not respond to support treatment have poorer outcomes and limited treatment options. Our experience suggests that HA bladder instillation is an effective and safe procedure in patients who had failed conservative treatment, leading to marked overall and complete response rates, especially when introduced promptly after diagnosis.
  • ||||||||||  Vistide (cidofovir) / Gilead, cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4572;    
    Patients who do not respond to support treatment have poorer outcomes and limited treatment options. Our experience suggests that HA bladder instillation is an effective and safe procedure in patients who had failed conservative treatment, leading to marked overall and complete response rates, especially when introduced promptly after diagnosis.
  • ||||||||||  Vistide (cidofovir) / Gilead, cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4571;    
    Patients who do not respond to support treatment have poorer outcomes and limited treatment options. Our experience suggests that HA bladder instillation is an effective and safe procedure in patients who had failed conservative treatment, leading to marked overall and complete response rates, especially when introduced promptly after diagnosis.
  • ||||||||||  leflunomide / Generic mfg.
    Enrollment open:  Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov) -  Jun 15, 2020   
    P1,  N=10, Recruiting, 
    In conclusion, LEF provided a better treatment response, along with lower reproductive toxicity, compared with CYC in initial-onset TA. Not yet recruiting --> Recruiting
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Review, Journal:  Interventions for renal vasculitis in adults. (Pubmed Central) -  Jun 14, 2020   
    AZA, methotrexate and leflunomide were effective as maintenance therapy. Further studies are required to more clearly delineate the appropriate place of newer agents within an evidence-based therapeutic strategy.
  • ||||||||||  prednisolone / Generic mfg., methotrexate / Generic mfg., leflunomide / Generic mfg.
    Clinical, Journal:  Association of cytokine patterns and clinical/laboratory parameters, medication and periodontal burden in patients with rheumatoid arthritis (RA). (Pubmed Central) -  May 29, 2020   
    IL-10 was also elevated with longer duration of prednisolone (< 5 mg daily) and leflunomide therapy...IL-17 was higher in subjects with fewer missing teeth if the following criteria were fulfilled: shorter prednisolone (< 5 mg) and methotrexate therapy, more swollen joints, longer morning stiffness...Subjects suffering from dental/periodontal burden show an aberrant systemic cytokine availability of serum IL-6, IL-10, IL-17 and IL-23 related to disease activity and medication. This examination underlines the complexity of potential interactions between disease activity and medication related to periodontal burden.
  • ||||||||||  methotrexate / Generic mfg.
    Clinical, Review, Journal, Combination therapy, Monotherapy:  JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. (Pubmed Central) -  May 28, 2020   
    These effects may explain why MTX leads to clinical effects similar to anti-TNFα biologics in monotherapy, but is less effective when compared to anti-IL6R in monotherapy, which acting upstream exerts major effects downstream on the JAK1-STAT3 pathway. The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.
  • ||||||||||  leflunomide / Generic mfg.
    Journal:  PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. (Pubmed Central) -  May 27, 2020   
    Therapeutic inhibition of the pyrimidine biosynthetic enzyme DHODH with leflunomide substantially impaired CRC liver metastatic colonization and hypoxic growth. Our findings provide a potential mechanistic basis for the epidemiologic association of anti-gluconeogenic drugs with improved CRC metastasis outcomes, reveal the exploitation of a gluconeogenesis enzyme for pyrimidine biosynthesis under hypoxia, and implicate DHODH and PCK1 as metabolic therapeutic targets in colorectal cancer metastatic progression.
  • ||||||||||  hydroxychloroquine / Generic mfg., methotrexate / Generic mfg., leflunomide / Generic mfg.
    [VIRTUAL] VIRAL ARTHRITIS: DESCRIPTIVE ANALYSIS OF A SERIES OF 131 PATIENTS (Poster View) -  May 22, 2020 - Abstract #EULAR2020EULAR_3968;    
    It appears with a sporadic, occasionally epidemic, pattern of presentation, predominantly in warm seasons. A clinical presentation as an oligoarthritis or an acute monoarthritis or even the positivity of autoimmunity markers, should not make us rule out this possible aetiology.
  • ||||||||||  methotrexate / Generic mfg., sulfasalazine / Generic mfg., leflunomide / Generic mfg.
    [VIRTUAL] THE USE OF A COMORBIDITY INDEX FOR PREDICTING CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING THEIR FIRST BIOLOGICAL AGENT (Poster View) -  May 22, 2020 - Abstract #EULAR2020EULAR_3862;    
    The majority exhibited a very high or high disease activity at baseline (median DAS28 3V 5.48 [4.70 – 6.19]) and 90% (n=226) of them were concomitantly using corticosteroids and/or other disease-modifying anti-rheumatic drugs (129 with methotrexate (MTX), 96 with leflunomide and 35 with sulfasalazine). Although our data point to a weak association between morbidities, assessed by the RDCI, and response to a first bDMARD, it is important to consider this simple and useful tool in future prospective and broader studies, since information bias regarding comorbidities may have been responsible for our results.
  • ||||||||||  [VIRTUAL] PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND RESOURCE UTILIZATION OF SJOGREN’S SYNDROME PATIENTS IN A LARGE US HEALTH NETWORK (Poster View) -  May 22, 2020 - Abstract #EULAR2020EULAR_3778;    
    Baseline Demographic and Clinical Pts Characteristics 1 cevimeline, pilocarpine hydrochloride, ophthalmic insert etc; 2 aspirin, ibuprofen, naproxen; 3 methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, myophenolate mofetil, azathioprine; 4 prednisone; 5 sarilumab, belimumab, ustekinumab, infliximab, adalimumab, certolizumab pegol, golimumab, etanercept, abatacept, tocilizumab, rituximab, tofacitinib, baricitinib Figure 1. Observation of higher comorbidities suggests substantial burden of SS pts on healthcare system, with majority of pts being diagnosed outside of rheumatology offices.